BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 247 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $9,723,000 | +4.9% | 100,150 | -26.1% | 1.14% | +1.3% |
| Q1 2021 | $9,265,000 | -39.6% | 135,550 | -24.3% | 1.13% | -55.2% |
| Q4 2020 | $15,343,000 | -8.2% | 179,000 | -30.4% | 2.52% | -21.9% |
| Q3 2020 | $16,708,000 | -24.3% | 257,000 | -14.9% | 3.22% | -31.3% |
| Q2 2020 | $22,072,000 | +75.1% | 301,900 | -18.7% | 4.70% | -5.0% |
| Q1 2020 | $12,608,000 | -55.0% | 371,250 | -27.8% | 4.94% | +10.5% |
| Q4 2019 | $28,025,000 | +1.2% | 514,500 | -22.6% | 4.47% | -28.0% |
| Q3 2019 | $27,701,000 | +142.7% | 664,450 | +155.1% | 6.21% | +244.9% |
| Q2 2019 | $11,415,000 | +2116.5% | 260,500 | +2505.0% | 1.80% | +1719.2% |
| Q1 2019 | $515,000 | +30.4% | 10,000 | 0.0% | 0.10% | +67.8% |
| Q2 2018 | $395,000 | – | 10,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
| Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
| ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
| Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
| Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
| Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |